Novavax, Inc. (NASDAQ:NVAX)
Industry: Biotechnology

Listed 9 Consecutive Market Days. On List as of 09/02/2005 Through 09/16/2005

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Current Quote*
Last: $11.220
Change: -1.000
Book: $1.868
Volume: 18,039,327

As Of: 10/06 16:10 ET
*Quotes delayed by 20min.

Graphs for NVAX


3 Month Graph


6 Month Graph


1 Year Graph